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Purpose
Mycobacterial disease is treatable and its spread is preventable. Even in the United 
States its’ insidious presentation and low incidence, can be overlooked when 
practitioners address pulmonary disease. We present a case of mycobacterial 
illness mistakenly treated as severe pneumonia.
Consideration for tuberculosis (TB) & non-tuberculous mycobacterial disease (NTM)
1. Data for spread of TB/ NTM mycobacterial disease in the US:
•The WHO estimates that 1/3 of the world’s population is infected with TB with a 
resurgence in both TB and NTM.
•TB low incidence in US but risk factors (RFs), while spread of NTM disease in the US 
is unknown. 
2. Diagnostic criteria has become more lenient and with expansion of specific 
radiological criteria more cases of TB diagnosed and treated1
3. Awareness of risk factors for mycobacterial disease (selected few4)
Immunocompromised Host Environmental Factors
- AIDS - incarceration
- Steroid treatment - homelessness
- Carcinoma - occupational exposure
- Transplant recipients
- Children
4. High risk progression latent TB infection to TB (selected risk factors)2
- HIV
- immunocompromised (Diabetes mellitus, steroid therapy)
- malignancies
- infants and children < 4 years of age
- body weight ≥ 10% below ideal body weight
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CASE REPORT Discussion
Future considerations
This report documents a common treatment algorithm, based on a differential 
focused on typical culprits for pulmonary infection. Latent mycobacterial 
infections in our community do exist, and can lead to fulminant TB especially in 
individuals who are immunocompromised and uncontrolled diabetics. 
Mycobacterial risk in these populations should be assessed. Screening tests, even 
in non-compliant individuals are easily obtainable. A focus should be placed on 
identifying patients at risk for exposure to TB and providing diagnosis and 
treatment for latent infection or active disease. 
Our residency program works out of a Federally Qualified Health Center, where 
our population is high risk for LTBI. Risk factors include: residing in shelters, 
homelessness, higher rates of intravenous drug use,  chronic conditions, and/or 
history of imprisonment. Many of these factors contribute to 
low rates of follow-up for screening with the tuberculin skin test. 
Ideal State: Identifying and screening high-risk patients with no previous testing or 
prior negative test results with the QFT. This is a blood test which does not require 
follow-up for results. Use a symptoms-based questionnaire for patients with 
known LTBI to monitor progression to active disease. QFT could be administered 
to those identified as high risk even with no previous testing or prior negative test 
results. As these tests result, evaluation with a chest X-ray would stratify our 
groups to either further evaluate for latent mycobacterial infections or to treat 
based on positive chest X-ray.  Educating all providers who care for these patients 
on whom to screen for TB and how to follow-up on positive results. Outcome 
measure would include: TB screening tests, follow up imaging, and treatment if 
indicated for LTBI or active infections.
Patient description:
- 43 year old Caucasian male with poorly controlled type 1 diabetes
- A1c 9.1%, with considerable neuropathy, non smoker, no drug use
- 1 month history of cough, weakness, night sweats/chills, weight loss, 
severe dyspnea on exertion
- Incarceration, 10 yrs ago (TB skin test positive with negative CXR)
Presented to ED in DKA. He was treated in ICU for euglycemia and his 
pulmonary disease was characterized as a bacterial pneumonia. 
- respiratory infectious disease panel was negative and he was treated with 
broad spectrum antibiotics and discharged. 
Hospital follow up a week post discharge, complains of continued dyspnea on 
exertion and weakness.  A careful examination of imaging report and history 
taking consisted with a timely screening for TB.
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Figure 2: Total number of reported U.S. TB cases and the associated rates 
for each of the past 6 years. Rate = cases/100,000 population. Rate has not 
decreased in last 2 years.
QuantiFERON gold test (QFT) was positive and our patient was admitted again, 
this time to our isolation inpatient service for evaluation. 
- His acid fast bacillus smear being positive, he was started on rifampin, isoniazid, 
pyrazinamide, ethambutol (RIPE) therapy. He was discharged after three negative 
sputum smears on the same therapy with cultures pending final characterization.
On hospital follow up, he was continuing his RIPE therapy. His blood glucoses 
were not well controlled with improvement in his respiratory status as he was 
ambulating with less dyspnea. No chills, fevers, night sweats. Moderate weight 
gain.
Our patient was lost to subsequent follow up. He had not been seen again by our 
ID colleagues. 
Principles:
•Identify/Screen patients at high risk for TB/ latent TB infection (LTBI)
•Screening modality in individuals with poor follow up
•Differential in immunocompromised patient must be broad
•Populations in TB endemic areas are known to have concomitant 
TB/pneumonia, in the low endemic areas such as the US, these cases are 
insidious5
What we’ve learned: someone that has symptoms and risk factors must be 
screened for mycobacterial disease
Figure 1: Resident of any type of correctional facility at the time of TB 
diagnosis. Total number of cases have dropped by percentage of total cases from 
correctional facilities has risen.
Picture 1 and Picture 2 –CT chest with
contrast coronal (left), and axial (above).
Strongly suggestive of tuberculosis. Mediastinal
hilar adenopathy, apical infiltrates. Notable of a
military infiltrative pattern.
